Study of the antimicrobial activity of new quinazoline derivatives against Staphylococcus aureus

   The aim of the study was to study the antimicrobial activity of new quinazoline derivatives against Staphylococcus aureus with the prediction of the structure-activity relationship.

   Material and methods. Primary antimicrobial screening of new quinazoline derivatives was carried out using the serial dilution method. The number of colonies was counted using the BIOMIC V3 software and hardware complex (Giles Scientific, USA). For statistical processing of the study results, the StatTech program (Russia) was used using the parametric method with the definition of Student’s t-test with Bonferroni correction. Prediction of direct biological targets was carried out using the PASS software tool. Structural parameters and octanol/water partition coefficient (LogP) were determined using ProTox 3.0.

   Results. The bacteriostatic effect of the substance VMA-23-10 against S. aureus was established in dilutions of 128, 64 and 32 μg/ml. It has been shown that VMA-23-10, distinguished by the presence of an isopropyl radical in the molecule, is characterized by greater lipophilicity. The mechanism of action of the substance VMA-23-10 was predicted.

   Conclusions. The conducted study made it possible to identify the leading compound among the studied derivatives, which exhibits a bacteriostatic effect against S. aureus. The difference in lipophilicity between VMA-23-10 and other molecules studied probably determines their different ability to penetrate the cell membrane of the pathogen. The predicted probability of the effect of the compound VMA-23-10 on serine/threonine protein kinases suggests that it exhibits an antimicrobial effect due to disruption of peptidoglycan synthesis, as well as suppression of the process of biofilm formation.

1. Jacobs L.M., Console P., Chen Y. Drug discovery in the field of β-lactams: an academic perspective. Antibiotics (Basel). 2024;13(1):59. doi: 10.3390/antibiotics13010059

2. Dos Santos J.F.S., Tintino S.R., da Silva A.R.P., Dos S Barbosa C.R., Scherf J.R., de S. Silveira Z., de Freitas T.S., de Lacerda Neto L.J., Barros L.M., de A. Menezes I.R., … Cunha F.A.B. Enhancement of the antibiotic activity by quercetin against Staphylococcus aureus efflux pumps. J. Bioenerg. Biomembr. 2021;53(2):157–167. doi: 10.1007/s10863-021-09886-4

3. Wacnik K., Rao V.A., Chen X., Lafage L., Pazos M., Booth S., Vollmer W., Hobbs J.K., Lewis R.J., Foster S.J. Penicillin-binding protein 1 (PBP1) of Staphylococcus aureus has multiple essential functions in cell division. MBio. 2022;13(4):e00669–22. doi: 10.1128/mbio.00669-22

4. Ibrahim O.O. Staphylococcus aureus a gram-positive coccid bacterium causing microbial infections, and toxins symptoms including food poisoning. EC Microbiol. 2020;16:61–76.

5. Аbitayeva G., Bulanin D., Мarchenko Е., Vangelista L. New therapeutic approaches for the treatment of staphylococcal infections. Meditsinskiy zhurnal Astany = Astana Medical Journal. 2020;105(3):70–78. [In Russian].

6. Hu Y., Meng J., Shi C., Hervin K., Fratamico P.M., Shi X. Characterization and comparative analysis of a second thermonuclease from Staphylococcus aureus. Microbiol. Res. 2013;168(3):174–182. doi: 10.1016/j.micres.2012.09.003

7. Costantino L., Barlocco D. Privileged structures as leads in medicinal chemistry. Curr. Med. Chem. 2006;13(1):65–85.

8. Auti P.S., George G., Paul A.T. Recent advances in the pharmacological diversification of quinazoline/quinazolinone hybrids. RSC Adv. 2020;10(68):41353–41392. doi: 10.1039/d0ra06642g

9. Starikova A.A., Tsibizova A.A., Zolotareva N.V., Merezhkina D.V., Ozerov A.A., Samotrueva M.A. New derivatives of quinazolinone as an object in the search for substances exhibiting a multitargeting effect. Sibirskiy nauchnyy meditsinskiy zhurnal = Siberian Scientific Medical Journal. 2024;44(1):155–171. [In Russian]. doi: 10.18699/SSMJ20240116

10. Vandevelde N.M., Tulkens P.M., van Bambeke F. Modulating antibiotic activity towards respiratory bacterial pathogens by co-medications: a multi-target approach. Drug Discov. Today. 2016;21(7):1114–1129. doi: 10.1016/j.drudis.2016.04.001

11. O’Shea R., Moser H.E. Physicochemical properties of antibacterial compounds: implications for drug discovery. J. Med. Chem. 2008;51(10):2871–2878. doi: 10.1021/jm700967e

12. Kikon R., Chetia D., Borthakur M. S., Patowary L., Tayeng D., Zothantluanga J.H. In-silico design and screening of quinolone derivatives against girase of staphylococcus. Current Trends in Pharmaceutical Research. 2022;9(1):1–16.

13. Khamidullina H.H., Ryabikova D.N. Classification of mixtures in accordance with the Globally harmonized System of Classification and Labelling of Chemical products (GHS). Toksikologicheskiy vestnik = Toxicological Review. 2014;(1):43–63. [In Russian].

14. Zakharevich N.V., Danilenko V.N. Serine/threonine protein kinases of bacteria are potential targets for regulation of human microbiota composition. Vestnik Rossiyskogo gosudarstvennogo meditsinskogo universiteta = Bulletin of the Russian State Medical University. 2017;(2):20–29. [In Russian].

15. Débarbouillé M., Dramsi S., Dussurget O., Nahori M.A., Vaganay E., Jouvion G., Cozzone A., Msadek T., Duclos B. Characterization of a serine/threonine kinase involved in virulence of Staphylococcus aureus. J. Bacteriol. 2009;191(13):4070–4081. doi: 10.1128/JB.01813-08